Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

Jennifer R. Brown, John C. Byrd, Steven E. Coutre, Don M. Benson, Ian W. Flinn, Nina D. Wagner-Johnston, Stephen E. Spurgeon, Brad S. Kahl, Celeste Bello, Heather K. Webb, Dave M. Johnson, Sissy Peterman, Daniel Li, Thomas M. Jahn, Brian J. Lannutti, Roger G. Ulrich, Albert S. Yu, Langdon L. Miller, Richard R. Furman

Blood (2014) 123 (22): 3390–3397.

https://doi.org/10.1182/blood-2013-11-535047

Published: 2014

Includes: Supplemental data

Journal Articles

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

Brad S. Kahl, Stephen E. Spurgeon, Richard R. Furman, Ian W. Flinn, Steven E. Coutre, Jennifer R. Brown, Don M. Benson, John C. Byrd, Sissy Peterman, Yoonjin Cho, Albert Yu, Wayne R. Godfrey, Nina D. Wagner-Johnston

Blood (2014) 123 (22): 3398–3405.

https://doi.org/10.1182/blood-2013-11-537555

Published: 2014

Journal Articles

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

Ian W. Flinn, Brad S. Kahl, John P. Leonard, Richard R. Furman, Jennifer R. Brown, John C. Byrd, Nina D. Wagner-Johnston, Steve E. Coutre, Don M. Benson, Sissy Peterman, Yoonjin Cho, Heather K. Webb, David M. Johnson, Albert S. Yu, Roger G. Ulrich, Wayne R. Godfrey, Langdon L. Miller, Stephen E. Spurgeon

Blood (2014) 123 (22): 3406–3413.

https://doi.org/10.1182/blood-2013-11-538546

Published: 2014

Journal Articles

CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Richard R. Furman, MD, John C. Byrd, MD, Jennifer R Brown, MD, PhD, Steven E. Coutre, MD, Don M Benson, Jr., MD, Nina D. Wagner-Johnston, Ian W. Flinn, MD, PhD, Brad S. Kahl, MD, Stephen E. Spurgeon, MD, Brian Lannutti, PhD, Neil A. Giese, Ph.D., Heather K Webb, Ph.D., Roger G Ulrich, Ph.D., Sissy Peterman, Leanne M. Holes, Albert S Yu, MD

Blood (2010) 116 (21): 55.

https://doi.org/10.1182/blood.V116.21.55.55

Published: 2010

Journal Articles

Clinical Pharmacokinetics of CAL-101, a p110δ Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration In Healthy Volunteers and Patients with Hematological Malignancies

Heather K Webb, Ph.D., Hao Chen, Ph.D., Albert S Yu, M.D., Sissy Peterman, Leanne Holes, Brian Lannutti, PhD, Langdon L. Miller, MD, Roger G Ulrich, Ph.D.

Blood (2010) 116 (21): 1774.

https://doi.org/10.1182/blood.V116.21.1774.1774

Published: 2010

Journal Articles

Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Brad Kahl, MD, John C. Byrd, MD, Ian W. Flinn, MD, PhD, Nina Wagner-Johnston, MD, Stephen Spurgeon, MD, Don M Benson, Jr, MD, Richard R. Furman, MD, Jennifer R Brown, MD, PhD, Steven Coutre, MD, Brian Lannutti, PhD, Neil A. Giese, Ph.D., Roger G Ulrich, Ph.D., Heather K Webb, Ph.D., Sissy Peterman, Leanne Holes, Albert S Yu, MD

Blood (2010) 116 (21): 1777.

https://doi.org/10.1182/blood.V116.21.1777.1777

Published: 2010

Journal Articles

A Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Combination with Rituximab and/or Bendamustine In Patients with Relapsed or Refractory B-Cell Malignancies.

Ian W. Flinn, MD, PhD, Marshall T. Schreeder, Nina Wagner-Johnston, Ralph V. Boccia, MD, John P. Leonard, MD, Steven E. Coutre, Leanne M. Holes, Sissy Peterman, Albert S. Yu, MD

Blood (2010) 116 (21): 2832.

https://doi.org/10.1182/blood.V116.21.2832.2832

Published: 2010

NARROW

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Clinical Pharmacokinetics of CAL-101, a p110δ Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration In Healthy Volunteers and Patients with Hematological Malignancies

Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

A Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Combination with Rituximab and/or Bendamustine In Patients with Relapsed or Refractory B-Cell Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Clinical Pharmacokinetics of CAL-101, a p110δ Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration In Healthy Volunteers and Patients with Hematological Malignancies

Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

A Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Combination with Rituximab and/or Bendamustine In Patients with Relapsed or Refractory B-Cell Malignancies.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only